Separate China Phase 1 study of MSB-2311 with several disease expansion cohorts

Trial Profile

Separate China Phase 1 study of MSB-2311 with several disease expansion cohorts

Planning
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs MSB 2311 (Primary)
  • Indications Cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Apr 2018 New trial record
    • 13 Apr 2018 According to a MabSpace Biosciences media release, this study i9s at the final stage of regulatory review, and is expected to be initiated soon upon CFDA approval.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top